Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer

FEBS Letters

Volumn 586, Issue 14, 2012, Pages 1984-1992

  Malkoski, Stephen P ^a   Wang, Xiao Jing ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Fanconi anemia; Juvenile polyposis Smads; Pancreatic cancer; Squamous cell carcinomas; TGF signaling

Indexed keywords

SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

BILE DUCT CARCINOMA; BREAST CARCINOMA; CANCER THERAPY; COLON CANCER; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FANCONI ANEMIA; GENE DELETION; GENE EXPRESSION REGULATION; GENE LOCATION; GENE LOSS; GENE MUTATION; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SMAD4 GENE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CHOLANGIOCARCINOMA; COLONIC NEOPLASMS; DISEASE PROGRESSION; FANCONI ANEMIA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; INTESTINAL POLYPOSIS; MALE; MICE; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84862757239     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2012.01.054     Document Type: Review

References (137)

1. F. Liu, A. Hata, J.C. Baker, J. Doody, J. Carcamo, R.M. Harland, and J. Massague A human Mad protein acting as a BMP-regulated transcriptional activator Nature 381 1996 620 623
2. G. Lagna, A. Hata, A. Hemmati-Brivanlou, and J. Massague Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways Nature 383 1996 832 836
3. G.J. Riggins Mad-related genes in the human Nat. Genet. 13 1996 347 349
4. Y. Shi, and J. Massague Mechanisms of TGF-beta signaling from cell membrane to the nucleus Cell 113 2003 685 700
5. J. Massague, J. Seoane, and D. Wotton Smad transcription factors Genes Dev. 19 2005 2783 2810
6. P. ten Dijke, and C.S. Hill New insights into TGF-beta-Smad signalling Trends Biochem. Sci. 29 2004 265 273
7. X.H. Feng, and R. Derynck Specificity and versatility in tgf-beta signaling through Smads Annu. Rev. Cell Dev. Biol. 21 2005 659 693
8. L. Levy, and C.S. Hill Alterations in components of the TGF-beta superfamily signaling pathways in human cancer Cytokine Growth Factor Rev. 17 2006 41 58
9. G.C. Blobe, W.P. Schiemann, and H.F. Lodish Role of transforming growth factor beta in human disease N. Engl. J. Med. 342 2000 1350 1358
10. Y.E. Zhang Non-Smad pathways in TGF-beta signaling Cell Res. 19 2009 128 139
11. P.M. Siegel, and J. Massague Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer Nat. Rev. Cancer 3 2003 807 821
12. S.A. Hahn DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1 Science 271 1996 350 353
13. K.M. Zbuk, and C. Eng Hamartomatous polyposis syndromes Nat. Clin. Pract. Gastroenterol. Hepatol. 4 2007 492 502
14. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J. Clin. 59 2009 225 249
15. E. Rozenblum Tumor-suppressive pathways in pancreatic carcinoma Cancer Res. 57 1997 1731 1734
16. V.T. Smit, A.J. Boot, A.M. Smits, G.J. Fleuren, C.J. Cornelisse, and J.L. Bos KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas Nucleic Acids Res. 16 1988 7773 7782
17. C. Caldas Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma Nat. Genet. 8 1994 27 32
18. H. Kalthoff P53 and K-RAS alterations in pancreatic epithelial cell lesions Oncogene 8 1993 289 298
19. R.E. Wilentz, C.A. Iacobuzio-Donahue, P. Argani, D.M. McCarthy, J.L. Parsons, C.J. Yeo, S.E. Kern, and R.H. Hruban Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression Cancer Res. 60 2000 2002 2006
20. C.A. Iacobuzio-Donahue DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer J. Clin. Oncol. 27 2009 1806 1813
21. A. Blackford SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer Clin. Cancer Res. 15 2009 4674 4679
22. M. Tascilar The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma Clin. Cancer Res. 7 2001 4115 4121
23. R.A. Smith, J. Tang, C. Tudur-Smith, J.P. Neoptolemos, and P. Ghaneh Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer Br. J. Cancer 104 2011 1440 1451
24. G. Gu, J. Dubauskaite, and D.A. Melton Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors Development 129 2002 2447 2457
25. Y. Kawaguchi, B. Cooper, M. Gannon, M. Ray, R.J. MacDonald, and C.V. Wright The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors Nat. Genet. 32 2002 128 134
26. N. Bardeesy Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer Genes Dev. 20 2006 3130 3146
27. K. Izeradjene Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas Cancer Cell 11 2007 229 243
28. K. Kojima, S.M. Vickers, N.V. Adsay, N.C. Jhala, H.G. Kim, T.R. Schoeb, W.E. Grizzle, and C.A. Klug Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia Cancer Res. 67 2007 8121 8130
29. X. Xu, B. Ehdaie, N. Ohara, T. Yoshino, and C.X. Deng Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice Oncogene 29 2010 674 686
30. N. Agrawal Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1 Science 333 2011 1154 1157
31. S.K. Kim, Y. Fan, V. Papadimitrakopoulou, G. Clayman, W.N. Hittelman, W.K. Hong, R. Lotan, and L. Mao DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma Cancer Res. 56 1996 2519 2521
32. V.A. Papadimitrakopoulou, Y. Oh, A. El-Naggar, J. Izzo, G. Clayman, and L. Mao Presence of multiple incontiguous deleted regions at the long arm of chromosome 18 in head and neck cancer Clin. Cancer Res. 4 1998 539 544
33. S. Takebayashi, T. Ogawa, K.Y. Jung, A. Muallem, H. Mineta, S.G. Fisher, R. Grenman, and T.E. Carey Identification of new minimally lost regions on 18q in head and neck squamous cell carcinoma Cancer Res. 60 2000 3397 3403
34. S. Bornstein Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation J. Clin. Invest. 119 2009 3408 3419
35. C. Maesawa MAD-related genes on 18q21.1, Smad2 and Smad4, are altered infrequently in esophageal squamous cell carcinoma Jpn. J. Cancer Res. 88 1997 340 343
36. H. Osawa, Y. Shitara, H. Shoji, A. Mogi, H. Kuwano, K. Hagiwara, and S. Takenoshita Mutation analysis of transforming growth factor beta type II receptor, Smad2, Smad3 and Smad4 in esophageal squamous cell carcinoma Int. J. Oncol. 17 2000 723 728
37. Kern, S.E. (2008) Molecular Basis of Cancer (3rd ed.). Mendelsohn, J. (Ed.), pp. 41-69.
38. W. Xie, S. Bharathy, D. Kim, B.G. Haffty, D.L. Rimm, and M. Reiss Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis Oncol. Res. 14 2003 61 73
39. X. Wang Growth inhibition induced by transforming growth factor-beta1 in human oral squamous cell carcinoma Mol. Biol. Rep. 36 2009 861 869
40. S. Natsugoe Smad4 and transforming growth factor beta1 expression in patients with squamous cell carcinoma of the esophagus Clin. Cancer Res. 8 2002 1838 1842
41. M. Fukuchi, N. Masuda, T. Miyazaki, M. Nakajima, H. Osawa, H. Kato, and H. Kuwano Decreased Smad4 expression in the transforming growth factor-beta signaling pathway during progression of esophageal squamous cell carcinoma Cancer 95 2002 737 743
42. Y. Teng, A.N. Sun, X.C. Pan, G. Yang, L.L. Yang, M.R. Wang, and X. Yang Synergistic function of Smad4 and PTEN in suppressing forestomach squamous cell carcinoma in the mouse Cancer Res. 66 2006 6972 6981
43. A.D. D'Andrea Susceptibility pathways in Fanconi's anemia and breast cancer N. Engl. J. Med. 362 2010 1909 1919
44. D.I. Kutler High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia Arch. Otolaryngol. Head Neck Surg. 129 2003 106 112
45. S. Houghtaling, C. Timmers, M. Noll, M.J. Finegold, S.N. Jones, M.S. Meyn, and M. Grompe Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice Genes Dev. 17 2003 2021 2035
46. B.G. Kim Smad4 signalling in T cells is required for suppression of gastrointestinal cancer Nature 441 2006 1015 1019
47. S. Bharathy, W. Xie, J.M. Yingling, and M. Reiss Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype Cancer Res. 68 2008 1656 1666
48. X. Yang, J.J. Letterio, R.J. Lechleider, L. Chen, R. Hayman, H. Gu, A.B. Roberts, and C. Deng Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta EMBO J. 18 1999 1280 1291
49. K.E. Hoot Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression J. Clin. Invest. 118 2008 2722 2732
50. B.A. Frederick, B.A. Helfrich, C.D. Coldren, D. Zheng, D. Chan, P.A. Bunn Jr., and D. Raben Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma Mol. Cancer Ther. 6 2007 1683 1691
51. H.E. Bryant Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 2005 913 917
52. H. Farmer Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
53. D.C. Chung The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis Gastroenterology 119 2000 854 865
54. S.D. Markowitz, and M.M. Bertagnolli Molecular origins of cancer: molecular basis of colorectal cancer N. Engl. J. Med. 361 2009 2449 2460
55. I. Nishisho Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients Science 253 1991 665 669
56. S.M. Powell, N. Zilz, Y. Beazer-Barclay, T.M. Bryan, S.R. Hamilton, S.N. Thibodeau, B. Vogelstein, and K.W. Kinzler APC mutations occur early during colorectal tumorigenesis Nature 359 1992 235 237
57. J.L. Bos, E.R. Fearon, S.R. Hamilton, M. Verlaan-de Vries, J.H. van Boom, A.J. van der Eb, and B. Vogelstein Prevalence of ras gene mutations in human colorectal cancers Nature 327 1987 293 297
58. S.J. Baker, S. Markowitz, E.R. Fearon, J.K. Willson, and B. Vogelstein Suppression of human colorectal carcinoma cell growth by wild-type p53 Science 249 1990 912 915
59. S. Thiagalingam Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers Nat. Genet. 13 1996 343 346
60. M. Miyaki Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis Oncogene 18 1999 3098 3103
61. A. Maitra, K. Molberg, J. Albores-Saavedra, and G. Lindberg Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease Am. J. Pathol. 157 2000 1105 1111
62. Y. Tang Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis Cancer Res. 65 2005 4228 4237
63. M. Isaksson-Mettavainio, R. Palmqvist, A.M. Dahlin, B. Van Guelpen, J. Rutegard, A. Oberg, and M.L. Henriksson High SMAD4 levels appear in microsatellite instability and hypermethylated colon cancers, and indicate a better prognosis Int. J. Cancer 2011
64. C. Le Goff Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre syndrome Nat. Genet. 44 2011 85 88
65. X. Yang, C. Li, X. Xu, and C. Deng The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice Proc. Natl. Acad. Sci. USA 95 1998 3667 3672
66. K. Takaku, M. Oshima, H. Miyoshi, M. Matsui, M.F. Seldin, and M.M. Taketo Intestinal tumorigenesis in compound mutant mice of both DPC4 (SMAD4) and APC genes Cell 92 1998 645 656
67. K. Takaku, H. Miyoshi, A. Matsunaga, M. Oshima, N. Sasaki, and M.M. Taketo Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice Cancer Res. 59 1999 6113 6117
68. X. Xu Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice Oncogene 19 2000 1868 1874
69. J.C. Hardwick, L.L. Kodach, G.J. Offerhaus, and G.R. van den Brink Bone morphogenetic protein signalling in colorectal cancer Nat. Rev. Cancer 8 2008 806 812
70. J.N. Hahn, V.G. Falck, and F.R. Jirik Smad4 deficiency in T cells leads to the Th17-associated development of premalignant gastroduodenal lesions in mice J. Clin. Invest. 121 2011 4030 4042
71. T. Kitamura SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion Nat. Genet. 39 2007 467 475
72. X. Xu Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice J. Clin. Invest. 116 2006 1843 1852
73. Y.K. Kang, W.H. Kim, and J.J. Jang Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma Hum. Pathol. 33 2002 877 883
74. Z. Ding SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression Nature 470 2011 269 273
75. L. Yang Targeted disruption of Smad4 in mouse epidermis results in failure of hair follicle cycling and formation of skin tumors Cancer Res. 65 2005 8671 8678
76. W. Qiao, A.G. Li, P. Owens, X. Xu, X.J. Wang, and C.X. Deng Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin Oncogene 25 2006 207 217
77. D. MacGrogan, M. Pegram, D. Slamon, and R. Bookstein Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas Oncogene 15 1997 1111 1114
78. A.A. Aitchison, A. Veerakumarasivam, M. Vias, R. Kumar, F.C. Hamdy, D.E. Neal, and I.G. Mills Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer Prostate 68 2008 661 674
79. P. Owens, E. Engelking, G. Han, S.M. Haeger, and X.J. Wang Epidermal Smad4 deletion results in aberrant wound healing Am. J. Pathol. 176 2010 122 133
80. W. Li Squamous cell carcinoma and mammary abscess formation through squamous metaplasia in Smad4/Dpc4 conditional knockout mice Development 130 2003 6143 6153
81. K. Eppert MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma Cell 86 1996 543 552
82. T. Sjoblom The consensus coding sequences of human breast and colorectal cancers Science 314 2006 268 274
83. W. Xie, D.L. Rimm, Y. Lin, W.J. Shih, and M. Reiss Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis Cancer J. 9 2003 302 312
84. W.R. Waldrip, E.K. Bikoff, P.A. Hoodless, J.L. Wrana, and E.J. Robertson Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo Cell 92 1998 797 808
85. M. Weinstein, X. Yang, C. Li, X. Xu, J. Gotay, and C.X. Deng Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2 Proc. Natl. Acad. Sci. USA 95 1998 9378 9383
86. J. Heyer, D. Escalante-Alcalde, M. Lia, E. Boettinger, W. Edelmann, C.L. Stewart, and R. Kucherlapati Postgastrulation Smad2-deficient embryos show defects in embryo turning and anterior morphogenesis Proc. Natl. Acad. Sci. USA 96 1999 12595 12600
87. M. Nomura, and E. Li Smad2 role in mesoderm formation, left-right patterning and craniofacial development Nature 393 1998 786 790
88. T. Hamamoto, H. Beppu, H. Okada, M. Kawabata, T. Kitamura, K. Miyazono, and M. Kato Compound disruption of smad2 accelerates malignant progression of intestinal tumors in apc knockout mice Cancer Res. 62 2002 5955 5961
89. C.A. Muro-Cacho, K. Rosario-Ortiz, S. Livingston, and T. Munoz-Antonia Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2 Clin. Cancer Res. 7 2001 1618 1626
90. W. Qiu, F. Schonleben, X. Li, and G.H. Su Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4 Cancer Lett. 245 2007 163 170
91. K.E. Hoot, M. Oka, G. Han, E. Bottinger, Q. Zhang, and X.J. Wang HGF upregulation contributes to angiogenesis in mice with keratinocyte-specific Smad2 deletion J. Clin. Invest. 120 2010 3606 3616
92. S.H. Tannehill-Gregg, D.F. Kusewitt, T.J. Rosol, and M. Weinstein The roles of Smad2 and Smad3 in the development of chemically induced skin tumors in mice Vet. Pathol. 41 2004 278 282
93. K. Uchida, M. Nagatake, H. Osada, Y. Yatabe, M. Kondo, T. Mitsudomi, A. Masuda, and T. Takahashi Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers Cancer Res. 56 1996 5583 5585
94. T.T. Maliekal, M.L. Antony, A. Nair, R. Paulmurugan, and D. Karunagaran Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer Oncogene 22 2003 4889 4897
95. M.C. Yakicier, M.B. Irmak, A. Romano, M. Kew, and M. Ozturk Smad2 and Smad4 gene mutations in hepatocellular carcinoma Oncogene 18 1999 4879 4883
96. N. Malhotra, E. Robertson, and J. Kang SMAD2 is essential for TGF beta-mediated Th17 cell generation J. Biol. Chem. 285 2010 29044 29048
97. G.J. Martinez Smad2 positively regulates the generation of Th17 cells J. Biol. Chem. 285 2010 29039 29043
98. J. Klein B cell-specific deficiency for Smad2 in vivo leads to defects in TGF-beta-directed IgA switching and changes in B cell fate J. Immunol. 176 2006 2389 2396
99. L. Wang Smad2 protein disruption in the central nervous system leads to aberrant cerebellar development and early postnatal ataxia in mice J. Biol. Chem. 286 2011 18766 18774
100. X.M. Meng Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis J. Am. Soc. Nephrol. 21 2010 1477 1487
101. S. Rajanahally, J.E. Agno, R.L. Nalam, M.B. Weinstein, K.L. Loveland, M.M. Matzuk, and Q. Li Genetic evidence that SMAD2 is not required for gonadal tumor development in inhibin-deficient mice Reprod. Biol. Endocrinol. 8 2010 69
102. W. Ju, A. Ogawa, J. Heyer, D. Nierhof, L. Yu, R. Kucherlapati, D.A. Shafritz, and E.P. Bottinger Deletion of Smad2 in mouse liver reveals novel functions in hepatocyte growth and differentiation Mol. Cell. Biol. 26 2006 654 667
103. I.M. van de Laar Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis Nat. Genet. 43 2011 121 126
104. G.J. Riggins, K.W. Kinzler, B. Vogelstein, and S. Thiagalingam Frequency of Smad gene mutations in human cancers Cancer Res. 57 1997 2578 2580
105. O. Korchynskyi, M. Landstrom, R. Stoika, K. Funa, C.H. Heldin, P. ten Dijke, and S. Souchelnytskyi Expression of Smad proteins in human colorectal cancer Int. J. Cancer 82 1999 197 202
106. S. Kawamata, K. Matsuzaki, M. Murata, T. Seki, K. Matsuoka, Y. Iwao, T. Hibi, and K. Okazaki Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis Inflamm. Bowel Dis. 17 2011 683 695
107. Y. Zhu, J.A. Richardson, L.F. Parada, and J.M. Graff Smad3 mutant mice develop metastatic colorectal cancer Cell 94 1998 703 714
108. M.B. Datto, J.P. Frederick, L. Pan, A.J. Borton, Y. Zhuang, and X.F. Wang Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction Mol. Cell. Biol. 19 1999 2495 2504
109. L. Maggio-Price, P. Treuting, W. Zeng, M. Tsang, H. Bielefeldt-Ohmann, and B.M. Iritani Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice Cancer Res. 66 2006 828 838
110. N.M. Sodir Smad3 deficiency promotes tumorigenesis in the distal colon of ApcMin/+ mice Cancer Res. 66 2006 8430 8438
111. M. Fukuchi Lack of activated Smad2 in transforming growth factor-beta signaling is an unfavorable prognostic factor in patients with esophageal squamous cell carcinoma J. Surg. Oncol. 94 2006 51 56
112. K. Vijayachandra, J. Lee, and A.B. Glick Smad3 regulates senescence and malignant conversion in a mouse multistage skin carcinogenesis model Cancer Res. 63 2003 3447 3452
113. A.G. Li, S.L. Lu, M.X. Zhang, C. Deng, and X.J. Wang Smad3 knockout mice exhibit a resistance to skin chemical carcinogenesis Cancer Res. 64 2004 7836 7845
114. D.S. Bae, N. Blazanin, M. Licata, J. Lee, and A.B. Glick Tumor suppressor and oncogene actions of TGFbeta1 occur early in skin carcinogenesis and are mediated by Smad3 Mol. Carcinog. 48 2009 441 453
115. G.S. Ashcroft Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response Nat. Cell Biol. 1 1999 260 266
116. K. Jinno, T. Takahashi, K. Tsuchida, E. Tanaka, and K. Moriyama Acceleration of palatal wound healing in Smad3-deficient mice J. Dent. Res. 88 2009 757 761
117. C.R. Owen, L. Yuan, and M.D. Basson Smad3 knockout mice exhibit impaired intestinal mucosal healing Lab. Invest. 88 2008 1101 1109
118. E. Tram, I. Ibrahim-Zada, L. Briollais, J.A. Knight, I.L. Andrulis, and H. Ozcelik Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario site of the breast cancer family registry (CFR) Breast Cancer Res. 13 2011 R77
119. P. Mhawech-Fauceglia, J. Kesterson, D. Wang, S. Akers, N.C. Dupont, K. Clark, S. Lele, and S. Liu Expression and clinical significance of the transforming growth factor-beta signalling pathway in endometrial cancer Histopathology 59 2011 63 72
120. S.U. Han, H.T. Kim, D.H. Seong, Y.S. Kim, Y.S. Park, Y.J. Bang, H.K. Yang, and S.J. Kim Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer Oncogene 23 2004 1333 1341
121. T.M. Shattuck, J. Costa, M. Bernstein, R.T. Jensen, D.C. Chung, and A. Arnold Mutational analysis of Smad3, a candidate tumor suppressor implicated in TGF-beta and menin pathways, in parathyroid adenomas and enteropancreatic endocrine tumors J. Clin. Endocrinol. Metab. 87 2002 3911 3914
122. L.A. Wolfraim Loss of Smad3 in acute T-cell lymphoblastic leukemia N. Engl. J. Med. 351 2004 552 559
123. Y.A. Yang, G.M. Zhang, L. Feigenbaum, and Y.E. Zhang Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2 Cancer Cell 9 2006 445 457
124. Q. Li, J.M. Graff, A.E. O'Connor, K.L. Loveland, and M.M. Matzuk SMAD3 regulates gonadal tumorigenesis Mol. Endocrinol. 21 2007 2472 2486
125. M. Oft, R.J. Akhurst, and A. Balmain Metastasis is driven by sequential elevation of H-ras and Smad2 levels Nat. Cell Biol. 4 2002 487 494
126. D. Zhong Homozygous deletion of SMAD4 in breast cancer cell lines and invasive ductal carcinomas Cancer Biol. Ther. 5 2006 601 607
127. M. Nagatake, Y. Takagi, H. Osada, K. Uchida, T. Mitsudomi, S. Saji, K. Shimokata, and T. Takahashi Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers Cancer Res. 56 1996 2718 2720
128. A. Baez, A. Cantor, S. Fonseca, M. Marcos-Martinez, L.A. Mathews, C.A. Muro-Cacho, and T. Munoz-Antonia Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma Clin. Cancer Res. 11 2005 3191 3197
129. E. Heinmoller, W. Dietmaier, H. Zirngibl, P. Heinmoller, W. Scaringe, K.W. Jauch, F. Hofstadter, and J. Ruschoff Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma Am. J. Pathol. 157 2000 83 92
130. T. Yatsuoka Association of poor prognosis with loss of 12q, 17p, and 18q, and concordant loss of 6q/17p and 12q/18q in human pancreatic ductal adenocarcinoma Am. J. Gastroenterol. 95 2000 2080 2085
131. T. Jonson, L. Gorunova, S. Dawiskiba, A. Andren-Sandberg, G. Stenman, P. ten Dijke, B. Johansson, and M. Hoglund Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer Genes Chromosomes Cancer 24 1999 62 71
132. T. Toga, Y. Nio, K. Hashimoto, T. Higami, and R. Maruyama The dissociated expression of protein and messenger RNA of DPC4 in human invasive ductal carcinoma of the pancreas and their implication for patient outcome Anticancer Res. 24 2004 1173 1178
133. J. Luttges, H. Galehdari, V. Brocker, I. Schwarte-Waldhoff, D. Henne-Bruns, G. Kloppel, W. Schmiegel, and S.A. Hahn Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis Am. J. Pathol. 158 2001 1677 1683
134. A.V. Biankin Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia Cancer Res. 61 2001 8830 8837
135. A.V. Biankin DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma J. Clin. Oncol. 20 2002 4531 4542
136. Z. Hua, Y.C. Zhang, X.M. Hu, and Z.G. Jia Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma World J. Gastroenterol. 9 2003 2764 2767
137. A.A. Khorana, Y.C. Hu, C.K. Ryan, R.A. Komorowski, G. Hostetter, and S.A. Ahrendt Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer J. Gastrointest. Surg. 9 2005 903 911